The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing ...

(HealthDay News) – Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis. To identify signs of early ...

Dr John Snowden, Consultant Haematologist and Director of Blood and Marrow Transplant at Sheffield Teaching Hospitals, said: ...

Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

Previous studies have demonstrated that orally administered bovine autoantigens can induce immune tolerance and improve symptoms in patients with autoimmune diseases. In a multicenter, double-blind ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...